Literature DB >> 6760967

A survey of prospective, controlled clinical trials of gentamicin, tobramycin, amikacin, and netilmicin.

L A Cone.   

Abstract

Data from 24 prospective, controlled clinical studies of the aminoglycosides gentamicin, tobramycin, amikacin, and netilmicin are reviewed. According to these findings, netilmicin is the safest and most effective of the four types (P less than 0.01, both comparisons), and gentamicin is more effective than tobramycin (P less than 0.05) and less ototoxic than amikacin (P less than 0.05).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6760967

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  4 in total

1.  Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients.

Authors:  Michael Mulheran; Pauline Hyman-Taylor; Kelvin H-V Tan; Sarah Lewis; David Stableforth; Alan Knox; Alan Smyth
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

2.  Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy.

Authors:  M Mulheran; C Degg; S Burr; D W Morgan; D E Stableforth
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

3.  Ceftazidime versus tobramycin-ticarcillin in the treatment of pneumonia and bacteremia.

Authors:  L A Cone; D R Woodard; D S Stoltzman; R G Byrd
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

Review 4.  Netilmicin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; S Chaplin; R H Sayce; K L Goa
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.